P3.01-087 Impact Factor Analysis for Efficacy and Prognosis of Anlotinib in NSCLC as Third-Line Treatment: Data from Trial ALTER 0303
Kai Li, Wang J, B. Han,Y. Zhao, Q. Wang, L. Zhang,Jianhua Shi,Zhehai Wang,Jiaxi He,Yuankai Shi,Y. Cheng,Wei Chen,Wang X,Yi Luo,Kejun Nan,Faguang Jin,J. Dong,Baolan Li,Yinlan Chen,Jian Zhou,Donglin Wang, Xuedong Zhou,Yan Yu,Lijuan Chen, A. Liu, Jiaoti Huang,Cheng Huang,Bangwei Cao,Jun Chen,R. Ma,Z. Yu,Cuimin Ding,Hanping Wang JOURNAL OF THORACIC ONCOLOGY（2017）
关键词
NSCLC,Anlotinib,third-line treatment
AI 理解论文
溯源树
样例
